Biogen Stock News

Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer's disease drug Aduhelm out in four years.  The

The study will enroll more than 1,300 patients with early-stage Alzheimers from the U.S. and internationally, the company said.

Shares of Biogen Inc. BIIB, +2.22% gained 0.9% in premarket trading on Thursday after the company said it plans to submit a protocol for a Phase 4 confirmatory study for its Alzheimer's disease drug t

Another factual information on the "Global Neurocognitive Disorder Treatment Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of

Analysts expect Biogen Inc. (NASDAQ:BIIB) to announce $2.63 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Twenty Nine analysts have provided estimates for Biogens earnings, with estimates ranging from $2.54 billion to $2.78 billion. Biogen reported sales of $2.85 billion during the same quarter last year, which indicates a negative []

Viatris Inc. announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogens Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically []

Related Stocks: PFE , ROKU , PLUG , ZM , MRNA , APPS , BB , AMC , LMT , A , ABNB , AI , BIIB , NKLA , DAL , CMG , FSLY , DISCA ,

The firm also reduced a number of holdings in the 3rd quarter Check out Ronald Muhlenkamp Stock Picks » Download GuruFolio Report of Ronald Muhlenkamp (Updated on 12/13/2021) Related Stocks: EQC , BIIB , NVTA , CCJ , MTZ , BMY , BRK.B , MSFT , CVS , SLB ,

DUBLIN--(BUSINESS WIRE)--The "North America Biosimilars Market 2020-2030 by Product Type, Indication, Manufacturing, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com''s offering. North America biosimilars market is expected to grow by 25.1% annually in the forecast period and reach $27.57 billion by 2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expi

Muhlenkamp & Co. Inc., the investment firm founded by Ronald Muhlenkamp (Trades, Portfolio), released its portfolio for the third quarter earlier this month.

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurologyBiogen to gain exclusive rights to TheraPanacea te…

CAMBRIDGE, Mass. and PARIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TheraPanacea today announced that they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship. The aim is to leverage machine learning (ML) and artificial intelligence (AI) analysis to develop digital health solutions that may improve patient care, accelerate drug development, and further the understanding of the underlying pathologies of neurological diseases.

Oregon will ask the Biden administration if its Medicaid program can avoid paying for drugs, like Biogen’s Alzheimer’s drug, Aduhelm, that were approved via the FDA’s fast-track pathway.

ARS Wealth Advisors Group LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,909 shares of the biotechnology companys stock, valued at approximately $540,000. Several other hedge funds and other institutional investors also recently bought []